Linked Life Data

3838405

Source:http://linkedlifedata.com/resource/pubmed/id/3838405

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3838405rdf:typepubmed:Citationlld:pubmed
pubmed-article:3838405lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:3838405lifeskim:mentionsumls-concept:C0232164lld:lifeskim
pubmed-article:3838405lifeskim:mentionsumls-concept:C1522565lld:lifeskim
pubmed-article:3838405lifeskim:mentionsumls-concept:C0026400lld:lifeskim
pubmed-article:3838405lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:3838405lifeskim:mentionsumls-concept:C0264716lld:lifeskim
pubmed-article:3838405lifeskim:mentionsumls-concept:C0439534lld:lifeskim
pubmed-article:3838405pubmed:issue3 Pt 2lld:pubmed
pubmed-article:3838405pubmed:dateCreated1985-4-19lld:pubmed
pubmed-article:3838405pubmed:abstractTextThe effects of molsidomine were studied in seven patients with refractory congestive heart failure by means of two-dimensional echocardiography. Four milligrams of molsidomine or placebo was sublingually administered in a double-blind crossover manner. End-diastolic dimension, end-systolic dimension, and mean velocity of circumferential fiber shortening were measured just below the mitral valve before drug or placebo administration and 1 hour later. No significant changes were observed with placebo. Heart rate and mean arterial pressure were not significantly modified with Molsidomine (80 to 83 bpm and 100 to 97 mm Hg, respectively). The reduction in end-diastolic dimension (67 to 61 mm; 9%; P less than 0.01) was slightly greater than the decline in end-systolic dimension (59 to 54 mm; 8%; p less than 0.01). The mean velocity of circumferential fiber shortening increased from 0.4 to 0.5 sec-1 but did not achieve statistical significance. Thus sublingual administration of molsidomine in patients with chronic heart failure reduces end-diastolic more than end-systolic dimension without effect on blood pressure, suggesting a predominant action on cardiac preload.lld:pubmed
pubmed-article:3838405pubmed:languageenglld:pubmed
pubmed-article:3838405pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3838405pubmed:citationSubsetAIMlld:pubmed
pubmed-article:3838405pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3838405pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3838405pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3838405pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3838405pubmed:statusMEDLINElld:pubmed
pubmed-article:3838405pubmed:monthMarlld:pubmed
pubmed-article:3838405pubmed:issn0002-8703lld:pubmed
pubmed-article:3838405pubmed:authorpubmed-author:SobolskiJ CJClld:pubmed
pubmed-article:3838405pubmed:authorpubmed-author:BerkenboomG...lld:pubmed
pubmed-article:3838405pubmed:authorpubmed-author:DegreS GSGlld:pubmed
pubmed-article:3838405pubmed:authorpubmed-author:StoupelE EEElld:pubmed
pubmed-article:3838405pubmed:authorpubmed-author:VandermotenP...lld:pubmed
pubmed-article:3838405pubmed:issnTypePrintlld:pubmed
pubmed-article:3838405pubmed:volume109lld:pubmed
pubmed-article:3838405pubmed:ownerNLMlld:pubmed
pubmed-article:3838405pubmed:authorsCompleteYlld:pubmed
pubmed-article:3838405pubmed:pagination691-3lld:pubmed
pubmed-article:3838405pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:3838405pubmed:meshHeadingpubmed-meshheading:3838405-...lld:pubmed
pubmed-article:3838405pubmed:meshHeadingpubmed-meshheading:3838405-...lld:pubmed
pubmed-article:3838405pubmed:meshHeadingpubmed-meshheading:3838405-...lld:pubmed
pubmed-article:3838405pubmed:meshHeadingpubmed-meshheading:3838405-...lld:pubmed
pubmed-article:3838405pubmed:meshHeadingpubmed-meshheading:3838405-...lld:pubmed
pubmed-article:3838405pubmed:meshHeadingpubmed-meshheading:3838405-...lld:pubmed
pubmed-article:3838405pubmed:meshHeadingpubmed-meshheading:3838405-...lld:pubmed
pubmed-article:3838405pubmed:meshHeadingpubmed-meshheading:3838405-...lld:pubmed
pubmed-article:3838405pubmed:meshHeadingpubmed-meshheading:3838405-...lld:pubmed
pubmed-article:3838405pubmed:meshHeadingpubmed-meshheading:3838405-...lld:pubmed
pubmed-article:3838405pubmed:meshHeadingpubmed-meshheading:3838405-...lld:pubmed
pubmed-article:3838405pubmed:year1985lld:pubmed
pubmed-article:3838405pubmed:articleTitleEffects of molsidomine on left ventricular dimensions and cardiac function in patients with chronic heart failure.lld:pubmed
pubmed-article:3838405pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3838405pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:3838405pubmed:publicationTypeControlled Clinical Triallld:pubmed